+55%

est. 2Y upside i

HealthcareSeries A

Medical language models to automate healthcare operations

Rank

#1504

Sector

Healthcare AI / Revenue Cycle Management

Est. Liquidity

~5Y

Data Quality

Data: Low

Latent is a high-conviction Series A bet in a large but increasingly contested market — appropriate only for candidates with high risk tolerance and a 5+ year horizon.

Last updated: April 15, 2026

Bull (22%)+250%

Latent captures 10%+ of the prior auth AI market, scaling to $150M+ ARR by 2029 with strong NRR across 150+ health system clients. A strategic acquisition by McKesson or a major payer at 8-10x ARR, or an IPO at $1.5-2B valuation, yields roughly a 2.5-3.5x return on the current $600M post-money valuation — strong but not venture-scale from this entry point.

Base (48%)+50%

Latent grows to 80-100 health system clients and $50-70M ARR but faces pricing compression from Epic and Waystar, limiting multiple expansion. A Series B at $850-950M follows in 18-24 months, producing modest paper gains while two additional funding rounds dilute current employees by 30-40% before any liquidity event.

Bear (30%)-75%

Insurer-led reduction of PA requirements (UnitedHealthcare, Humana committing to streamline PA by 2026) materially shrinks Latent's core TAM, and Epic bundles competing functionality natively causing churn. A down round below $300M or acqui-hire results in near-total loss of common equity value after $80M+ in liquidation preferences are satisfied first.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Funding Intensity

1330%

Total disclosed funding of $80M against a $600M post-money Series A valuation gives a ~13.3% preference stack ratio, meaning investors must recoup $80M before common shareholders see any proceeds in a sub-$600M exit scenario.

Dilution Risk

high

As a Series A company likely needing 2-3 more rounds before a liquidity event, current employees face estimated total dilution of 40-60% from today to exit, significantly compressing per-share common equity value.

Secondary Liquidity

none

No evidence of secondary market activity for Latent shares; health-tech Series A companies rarely develop active secondary markets until late Series C or pre-IPO tender offers.

Questions to Ask at the Interview

Strategic questions based on Latent's data — designed to show you've done your homework.

  • 1

    “What is your current ARR and net revenue retention, and how has NRR trended as you've scaled from 4 to 45+ health systems — are health systems expanding usage after go-live?”

  • 2

    “How does Latent's Clinical Reasoning Engine remain defensible if Epic decides to build prior auth automation natively into Epic Payer Platform — what is your strategic moat beyond the current integrations?”

  • 3

    “What is the strike price of options being granted today relative to the $600M Series A preferred price, what does the option pool look like post-round, and has the board discussed any secondary liquidity programs for early employees?”

Community

Valuation Sentiment

Our model estimates +55% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.